dermorphin and tyrosyl-arginyl-phenylalanyl-lysinamide

dermorphin has been researched along with tyrosyl-arginyl-phenylalanyl-lysinamide* in 2 studies

Other Studies

2 other study(ies) available for dermorphin and tyrosyl-arginyl-phenylalanyl-lysinamide

ArticleYear
Identification of ex vivo catabolites of peptides with doping potential in equine plasma by HILIC-HRMS.
    Drug testing and analysis, 2020, Volume: 12, Issue:6

    Bioactive peptides pose a great threat to sports integrity. The detection of these peptides is essential for enforcing their prohibition in sports. Identifying the catabolites of these peptides that are formed ex vivo in plasma may improve their detection. In the present study, the stability of 27 bioactive peptides with protection at both termini in equine plasma was examined under different incubation conditions, using HILIC coupled to HRMS. Of the 27 peptides, 13 were stable after incubation at 37°C for 72 hr, but the remaining 14 were less stable. Ex vivo catabolites of these 14 peptides were detected using their theoretical masses generated in silico, their appearance was monitored over the time course of incubation, and their identity was verified by their product ion spectra. Catabolites identified for chemotactic peptide, DALDA, dmtDALDA, deltorphins I and II, Hyp

    Topics: Amino Acid Sequence; Animals; Biotransformation; Chromatography, High Pressure Liquid; Computer Simulation; Doping in Sports; Growth Hormone-Releasing Hormone; Horses; Magnetic Resonance Spectroscopy; Mass Spectrometry; Oligopeptides; Opioid Peptides; Peptides; Solid Phase Extraction; Substance Abuse Detection

2020
Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide.
    European journal of pharmacology, 2001, May-04, Volume: 419, Issue:1

    The dermorphin-derived peptide [Dmt(1)]DALDA (H-Dmt-D-Arg-Phe-Lys-NH(2)), labels mu-opioid receptors with high affinity and selectivity in receptor binding assays. In mouse, radiant heat tail-flick assay [Dmt(1)]DALDA produced profound spinal and supraspinal analgesia, being approximately 5000- and 100-fold more potent than morphine on a molar basis, respectively. When administered systemically, [Dmt(1)]DALDA was over 200-fold more potent than morphine. Pharmacologically, [Dmt(1)]DALDA was distinct from morphine. [Dmt(1)]DALDA displayed no cross-tolerance to morphine in the model used and it retained supraspinal analgesic activity in morphine-insensitive CXBK mice. Supraspinally, it also differed from morphine in its lack of sensitivity towards naloxonazine. Finally, in antisense mapping studies, [Dmt(1)]DALDA was insensitive to MOR-1 exon probes that reduced morphine analgesia, implying a distinct receptor mechanism of action. Thus, [Dmt(1)]DALDA is an interesting and extraordinarily potent, systemically active peptide analgesic, raising the possibility of novel approaches in the design of clinically useful drugs.

    Topics: Analgesics; Animals; Drug Tolerance; Humans; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Oligodeoxyribonucleotides, Antisense; Oligopeptides; Opioid Peptides; Pain Measurement; Receptors, Opioid, mu; Time Factors

2001